Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections

References

• Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(2):155–164.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Benjamin DK Jr., et al. 10 x ‘20 progress–development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis. 2013;56(12):1685–1694.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
   PubMed Web of Science ®Google Scholar
• Coleman K. Diazabicyclooctanes (DBOs): a potent new class of non-beta-lactam beta-lactamase inhibitors. Curr Opin Microbiol. 2011;14(5):550–555.
   PubMed Web of Science ®Google Scholar
• Bush K. The ABCD’s of beta-lactamase nomenclature. J Infect Chemother. 2013;19(4):549–559.
   PubMed Web of Science ®Google Scholar
• Bush K. Proliferation and significance of clinically relevant beta-lactamases. Ann N Y Acad Sci. 2013;1277:84–90.
   PubMed Web of Science ®Google Scholar
• Bush K. Carbapenemases: partners in crime. J Global Antimicrob Resist. 2013;1(1):7–16.
   PubMed Web of Science ®Google Scholar
• Chen LF, Freeman JT, Nicholson B, et al. Widespread dissemination of CTX-M-15 genotype extended-spectrum-beta-lactamase-producing enterobacteriaceae among patients presenting to community hospitals in the southeastern United States. Antimicrob Agents Chemother. 2014;58(2):1200–1202.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Johnson JR. A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2014;58(9):4997–5004.
   PubMed Web of Science ®Google Scholar
• Petty NK, Ben Zakour NL, Stanton-Cook M, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A. 2014;111(15):5694–5699.
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201.
   PubMed Web of Science ®Google Scholar
• Bush K. A resurgence of beta-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015;46(5):483–493.
   PubMed Web of Science ®Google Scholar
• Maseda E, Aguilar L, Gimenez M-J, et al. Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections. Expert Rev Anti Infect Ther. 2014;12(11):1311–1324.
   PubMed Web of Science ®Google Scholar
• Neu HC, Labthavikul P. Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982;21(1):11–18.
   PubMed Web of Science ®Google Scholar
• Lagace-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of gram-negative bacterial infections. Core Evid. 2014;9:13–25.
   PubMedGoogle Scholar
• Zhanel GG, Lawson CD, Adam H, et al. Ceftazidime-avibactam: a novel cephalosporin/beta-lactamase inhibitor combination. Drugs. 2013;73(2):159–177.
   PubMed Web of Science ®Google Scholar
• Ehmann DE, Jahic H, Ross PL, et al. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc Natl Acad Sci U S A. 2012;109(29):11663–11668.
   PubMed Web of Science ®Google Scholar
• Stachyra T, Pechereau MC, Bruneau JM, et al. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob Agents Chemother. 2010;54(12):5132–5138.
   PubMed Web of Science ®Google Scholar
• Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother. 2004;54(2):410–417.
   PubMed Web of Science ®Google Scholar
• Stachyra T, Levasseur P, Pechereau MC, et al. In vitro activity of the {beta}-lactamase inhibitor NXL104 against KPC-2 carbapenemase and enterobacteriaceae expressing KPC carbapenemases. J Antimicrob Chemother. 2009;64(2):326–329.
   PubMed Web of Science ®Google Scholar
• Das S, Li J, Armstrong J, et al. Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. Pharmacol Res Perspect. 2015;3(5):e00172.
   Google Scholar
• Merdjan H, Rangaraju M, Tarral A. Safety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studies. Clin Drug Investig. 2015;35(5):307–317.
   PubMed Web of Science ®Google Scholar
• Tominaga N, Edeki T, Li J, et al. Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. J Infect Chemother. 2015;21(8):551–558.
   PubMed Web of Science ®Google Scholar
• Li J, Learoyd M, Qiu F, et al. A randomized, phase I study to assess the safety, tolerability and pharmacokinetics of ceftazidime-avibactam in healthy Chinese subjects. Clin Drug Investig. 2016;36(2):119–126.
   PubMed Web of Science ®Google Scholar
• Avycaz (Ceftazidime-Avibactam). Package insert. Cincinnati, OH: Forest Pharmaceuticals; 2015.
   Google Scholar
• Keepers TR, Gomez M, Celeri C, et al. Bactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against beta-lactamase-producing enterobacteriaceae and pseudomonas aeruginosa. Antimicrob Agents Chemother. 2014;58(9):5297–5305.
   PubMed Web of Science ®Google Scholar
• Housman ST, Crandon JL, Nichols WW, et al. Efficacies of ceftazidime-avibactam and ceftazidime against pseudomonas aeruginosa in a murine lung infection model. Antimicrob Agents Chemother. 2014;58(3):1365–1371.
   PubMed Web of Science ®Google Scholar
• Grayson ML, Crowe SM, McCarthy JS, et al. Kucers’ the use of antibiotics sixth edition, a clinical review of antibacterial, antifungal and antiviral drugs. Hoboken: CRC Press; 2010.
   Google Scholar
• Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev. 2007;20(3):440–458.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1–10.
   PubMed Web of Science ®Google Scholar
• Bhagunde P, Chang KT, Hirsch EB, et al. Novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob Agents Chemother. 2012;56(5):2237–2240.
   PubMed Web of Science ®Google Scholar
• Coleman K, Levasseur P, Girard AM, et al. Activities of ceftazidime and avibactam against beta-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014;58(6):3366–3372.
   PubMed Web of Science ®Google Scholar
• Berkhout J, Melchers MJ, Van Mil AC, et al. In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays. Antimicrob Agents Chemother. 2015;59(2):1138–1144.
   PubMed Web of Science ®Google Scholar
• Dallow J, Otterson LG, Huband MD, et al. Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes. Int J Antimicrob Agents. 2014;44(6):552–556.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing. Wayne (PA): Clinical and Laboratory Standards Institute; 2014.
   Google Scholar
• EUCAST. European committee on antimicrobial susceptibility testing: clinical breakpoints. EUCAST. European Society of Clinical Microbiology and Infectious Diseases; 2016 Available at www.eucast.org
   Google Scholar
• Jones RN, Holliday NM, Krause KM. Validation of sensititre dry-form broth microdilution panels for susceptibility testing of ceftazidime-avibactam, a broad-spectrum-beta-lactamase inhibitor combination. Antimicrob Agents Chemother. 2015;59(8):5036–5039.
   PubMed Web of Science ®Google Scholar
• Halimi D, Stone G, Bulcher F, et al. Comparative evaluation of ceftazidime-avibactam MIC testing with Etest CZA256 and CLSI broth microdilution methods. San Diego (CA): ICAAC; 2015.
   Google Scholar
• Sader HS, Castanheira M, Flamm RK, et al. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother. 2014;58(3):1684–1692.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Farrell DJ, Sader HS, et al. Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal and urinary tract infections in US medical centres (2012). J Antimicrob Chemother. 2014;69(6):1589–1598.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Farrell SE, Krause KM, et al. Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. Antimicrob Agents Chemother. 2014;58(2):833–838.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Mills JC, Costello SE, et al. Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of beta-lactamase-producing strains. Antimicrob Agents Chemother. 2015;59(6):3509–3517.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Sader HS, Farrell DJ, et al. Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). Diagn Microbiol Infect Dis. 2014;80(3):233–238.
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Farrell DJ, et al. Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). Diagn Microbiol Infect Dis. 2015;83(4):389–394.
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Flamm RK, et al. Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. Int J Antimicrob Agents. 2015;46(1):53–59.
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Mendes RE, et al. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Antimicrob Agents Chemother. 2015;59(6):3656–3659.
   PubMed Web of Science ®Google Scholar
• Denisuik AJ, Karlowsky JA, Denisuik T, et al. In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible gram-negative clinical isolates obtained from patients in Canadian hospitals. Antimicrob Agents Chemother. 2015;59(6):3623–3626.
   PubMed Web of Science ®Google Scholar
• Flamm RK, Stone GG, Sader HS, et al. Avibactam reverts the ceftazidime MIC90 of European gram-negative bacterial clinical isolates to the epidemiological cut-off value. J Chemother. 2014;26(6):333–338.
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard AM, Claudon M, et al. In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother. 2012;56(3):1606–1608.
   PubMed Web of Science ®Google Scholar
• Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2012;39(1):86–89.
   PubMed Web of Science ®Google Scholar
• Lagace-Wiens PR, Tailor F, Simner P, et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother. 2011;55(5):2434–2437.
   PubMed Web of Science ®Google Scholar
• Endimiani A, Choudhary Y, Bonomo RA. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob Agents Chemother. 2009;53(8):3599–3601.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang F, Zhao C, et al. In vitro activities of ceftazidime-avibactam and aztreonam-avibactam against 372 gram-negative bacilli collected in 2011 and 2012 from 11 teaching hospitals in China. Antimicrob Agents Chemother. 2014;58(3):1774–1778.
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard AM, Miossec C, et al. In vitro antibacterial activity of the ceftazidime-avibactam combination against enterobacteriaceae, including strains with well-characterized beta-lactamases. Antimicrob Agents Chemother. 2015;59(4):1931–1934.
   PubMed Web of Science ®Google Scholar
• Mutters NT, Zimmermann S, Kaase M, et al. Activity of temocillin, mecillinam, ceftazidime, and ceftazidime/avibactam against carbapenem-nonsusceptible Enterobacteriaceae without carbapenemase production. Eur J Clin Microbiol Infect Dis. 2015;34(12):2429–2437.
   PubMed Web of Science ®Google Scholar
• Pitart C, Marco F, Keating TA, et al. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015;59(6):3059–3065.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2011;55(1):390–394.
   PubMed Web of Science ®Google Scholar
• Walkty A, DeCorby M, Lagace-Wiens PR, et al. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob Agents Chemother. 2011;55(6):2992–2994.
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother. 2010;65(11):2376–2381.
   PubMed Web of Science ®Google Scholar
• Yoshizumi A, Ishii Y, Aoki K, et al. In vitro susceptibility of characterized beta-lactamase-producing gram-negative bacteria isolated in Japan to ceftazidime-, ceftaroline-, and aztreonam-avibactam combinations. J Infect Chemother. 2015;21(2):148–151.
   PubMed Web of Science ®Google Scholar
• Citron DM, Tyrrell KL, Merriam V, et al. In vitro activity of ceftazidime-NXL104 against 396 strains of beta-lactamase-producing anaerobes. Antimicrob Agents Chemother. 2011;55(7):3616–3620.
   PubMed Web of Science ®Google Scholar
• Shields RK, Clancy CJ, Hao B, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother. 2015;59(9):5793–5797.
   PubMed Web of Science ®Google Scholar
• Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the Omega-loop. J Antimicrob Chemother. 2015;70(8):2279–2286.
   PubMed Web of Science ®Google Scholar
• Winkler ML, Papp-Wallace KM, Taracila MA, et al. Avibactam and inhibitor-resistant SHV beta-lactamases. Antimicrob Agents Chemother. 2015;59(7):3700–3709.
   PubMed Web of Science ®Google Scholar
• Levasseur P, Girard AM, Lavallade L, et al. Efficacy of a Ceftazidime-Avibactam combination in a murine model of Septicemia caused by Enterobacteriaceae species producing ampc or extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2014;58(11):6490–6495.
   PubMed Web of Science ®Google Scholar
• MacVane SH, Crandon JL, Nichols WW, et al. In vivo efficacy of humanized exposures of Ceftazidime-Avibactam in comparison with Ceftazidime against contemporary Enterobacteriaceae isolates. Antimicrob Agents Chemother. 2014;58(11):6913–6919.
   PubMed Web of Science ®Google Scholar
• Borgonovi M, Miossec C, Lowther J. The efficacy of ceftazidime combined with NXL104, a novel beta-lactamase inhibitor, in a mouse model of kidney infections induced by beta-lactamase producing Enterobacteriaceae. Abstract P794. Clin Microbiol Infect. 2007;13(Suppl. 2):S199–200. Plus poster presented at 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 Mar 31–Apr 3; Munich.
   Google Scholar
• Endimiani A, Hujer KM, Hujer AM, et al. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55(1):82–85.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Schuck VJ, Banevicius MA, et al. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2012;56(12):6137–6146.
   PubMed Web of Science ®Google Scholar
• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133–164.
   PubMed Web of Science ®Google Scholar
• Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68(5):1183–1192.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Gonzalez Patzan LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28(12):1921–1931.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Castanheira M, Gasink L, et al. beta-Lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates. Antimicrob Agents Chemother. 2015;60(3):1328–1335.
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Gasink L, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection - results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016 Mar 8. doi:10.1093/cid/ciw133. [Epub ahead of print]
   PubMedGoogle Scholar
• Positive Phase III Results Demonstrate Efficacy Of Antibiotic Medicine AVYCAZ™ (ceftazidime-avibactam) In Complicated Urinary Tract Infections. Allergen, Inc. [ cited 2016 Jan 20]. Available from: http://www.allergan.com/news/news/thomson-reuters/positive-phase-iii-results-demonstrate-efficacy-of)
   Google Scholar
• Carmeli Y, Armstrong J, Laud PJ et al. Efficacy and safety of ceftazidime-avibactam and best available therapy in the treatment of ceftazidime-resistant infections - results from a Phase III study. Poster presentation, ECCMID, LBEV0061b. 2015.
   Google Scholar
• Das S, Armstrong J, Mathews D, et al. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. J Clin Pharmacol. 2014;54(3):331–340.
   PubMed Web of Science ®Google Scholar
• Rashid MU, Rosenborg S, Panagiotidis G, et al. Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota. Int J Antimicrob Agents. 2015;46(1):60–65.
   PubMed Web of Science ®Google Scholar
• Infectious Diseases Society of America, Spellberg B, Blaser M, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(Suppl 5):S397–428.
   PubMedGoogle Scholar
• Grayson ML, Macesic N, Trevillyan J, et al. Fosfomycin for treatment of prostatitis: new tricks for old dogs. Clin Infect Dis. 2015;61(7):1141–1143.
   PubMed Web of Science ®Google Scholar
• Gardiner BJ, Mahony AA, Ellis AG, et al. Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis. 2014;58(4):e101–105.
   PubMed Web of Science ®Google Scholar
• Ehmann DE, Jahic H, Ross PL, et al. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases. J Biol Chem. 2013;288(39):27960–27971.
   PubMed Web of Science ®Google Scholar
• Pages JM, Peslier S, Keating TA, et al. The role of the outer membrane and porins in the susceptibility of beta-lactamase-producing Enterobacteriaceae to ceftazidime-avibactam. Antimicrob Agents Chemother. 2015;60(3):1349–1359.
   PubMed Web of Science ®Google Scholar
• Xu H, Hazra S, Blanchard JS. NXL104 irreversibly inhibits the beta-lactamase from Mycobacterium tuberculosis. Biochemistry. 2012;51(22):4551–4557.
   PubMed Web of Science ®Google Scholar
• Berkhout J, Melchers MJ, Van Mil AC, et al. Pharmacodynamics of Ceftazidime and Avibactam in neutropenic mice with thigh- or lung-infection. Antimicrob Agents Chemother. 2015;60(1):368–375.
   PubMed Web of Science ®Google Scholar
• Curcio D. Activity of a novel combination against multidrug-resistant nonfermenters: ceftazidime plus NXL104. Expert Rev Anti Infect Ther. 2011;9(2):173–176.
   PubMed Web of Science ®Google Scholar
• Lahiri SD, Giacobbe RA, Johnstone MR, et al. Activity of avibactam against Enterobacter cloacae producing an extended-spectrum class C beta-lactamase enzyme. J Antimicrob Chemother. 2014;69(11):2942–2946.
   PubMed Web of Science ®Google Scholar
• Li H, Estabrook M, Jacoby GA, et al. In vitro susceptibility of characterized beta-lactamase-producing strains tested with avibactam combinations. Antimicrob Agents Chemother. 2015;59(3):1789–1793.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J Antimicrob Chemother. 2008;62(5):1053–1056.
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Winkler ML, Gatta JA, et al. Reclaiming the efficacy of beta-lactam-beta-lactamase inhibitor combinations: avibactam restores the susceptibility of CMY-2-producing Escherichia coli to ceftazidime. Antimicrob Agents Chemother. 2014;58(8):4290–4297.
   PubMed Web of Science ®Google Scholar
• Caravaca-Fontan F, Jimenez-Alvaro S, Marcen-Letosa R, et al. Ceftazidime-avibactam in urinary tract infections due to carbapenemase-producing Klebsiella in kidney transplantation. Nefrologia. 2015;35(4):412–413.
   PubMed Web of Science ®Google Scholar
• Humphries RM, Yang S, Hemarajata P, et al. First report of ceftazidime-avibactam resistance in a KPC-3 expressing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;59(10):6605–6607.
   PubMed Web of Science ®Google Scholar
• Lahiri SD, Walkup GK, Whiteaker JD, et al. Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC. J Antimicrob Chemother. 2015;70(6):1650–1658.
   PubMed Web of Science ®Google Scholar
• Livermore DM, Warner M, Jamrozy D, et al. In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 Carbapenemase. Antimicrob Agents Chemother. 2015;59(9):5324–5330.
   PubMed Web of Science ®Google Scholar
• Papp-Wallace KM, Winkler ML, Taracila MA, et al. Variants of beta-lactamase KPC-2 that are resistant to inhibition by avibactam. Antimicrob Agents Chemother. 2015;59(7):3710–3717.
   PubMed Web of Science ®Google Scholar
• Thomson GK, Snyder JW, McElheny CL, et al. Co-production of KPC-18 and VIM-1 Carbapenemases by Enterobacter cloacae: implications for newer beta-lactam-beta-lactamase inhibitor combinations. J Clin Microbiol. 2015;54(3):791–794.
   PubMed Web of Science ®Google Scholar
• Winkler ML, Papp-Wallace KM, Hujer AM, et al. Unexpected challenges in treating multidrug-resistant gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015;59(2):1020–1029.
   PubMed Web of Science ®Google Scholar
• Bebrone C, Lassaux P, Vercheval L, et al. Current challenges in antimicrobial chemotherapy: focus on ss-lactamase inhibition. Drugs. 2010;70(6):651–679.
   PubMed Web of Science ®Google Scholar
• Bush K, Macielag MJ. New beta-lactam antibiotics and beta-lactamase inhibitors. Expert Opin Ther Pat. 2010;20(10):1277–1293.
   PubMed Web of Science ®Google Scholar
• Garber K. A beta-lactamase inhibitor revival provides new hope for old antibiotics. Nat Rev Drug Discov. 2015;14(7):445–447.
   PubMed Web of Science ®Google Scholar
• Mawal Y, Critchley IA, Riccobene TA, et al. Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. Expert Rev Clin Pharmacol. 2015;8(6):691–707.
   PubMed Web of Science ®Google Scholar
• Nicolau DP. Focus on ceftazidime-avibactam for optimizing outcomes in complicated intra-abdominal and urinary tract infections. Expert Opin Investig Drugs. 2015;24(9):1261–1273.
   PubMed Web of Science ®Google Scholar
• Thompson CA. Ceftazidime with beta-lactamase inhibitor approved for complicated infections. Am J Health Syst Pharm. 2015;72(7):511.
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Rybak JM, Rybak MJ. The beta-lactams strike sack: ceftazidime-avibactam. Pharmacotherapy. 2015;35(8):755–770.
   PubMed Web of Science ®Google Scholar